(FM) Inmunología
Departamento académico
Institute of Oncology Ljubljana
Liubliana, EsloveniaPublications en collaboration avec des chercheurs de Institute of Oncology Ljubljana (1)
2022
-
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
Cancer Discovery, Vol. 12, Núm. 5, pp. 1248-1265